<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474708</url>
  </required_header>
  <id_info>
    <org_study_id>0600B2-4418</org_study_id>
    <nct_id>NCT00474708</nct_id>
  </id_info>
  <brief_title>Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients</brief_title>
  <official_title>The Efficacy of Venlafaxine XR (Efexor XR®) Versus SSRIs &amp; Conventional Antidepressants in Depressed Patients Switched From Prior Antidepressants in Psychiatric Outpatient Care Settings in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, multi-center study conducted in a typical
      psychiatric outpatient practice in China. This study is intended to collect data on the
      efficacy and safety of venlafaxine XR (Efexor XR®) versus SSRIs and conventional
      antidepressants in depressed patients that previously failed antidepressant treatment. This
      data will be used to guide psychiatrists on recommendations for clinic use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving Remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1151</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Effexor XR Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.SSRI or Conventional Antidepressant Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effexor</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Males or females, 18 -65 years of age

          -  Outpatients

          -  Major depressive disorder based on DSM-IV criteria

          -  The baseline score of 17-item HAM-D³17

          -  Switchers from prior antidepressants, who have had no satisfactory improvement
             (normally after a minimum of 8weeks of treatment), with an approved antidepressant
             medication or have experienced intolerance due to side effects to their antidepressant
             medication based on clinical discretion

          -  Provide written informed consent

          -  If female is of childbearing potential, must be confirmed no pregnancy at baseline,
             and use a medically acceptable method of contraception throughout the study.

        Main Exclusion Criteria:

          -  Hypersensitivity to venlafaxine;

          -  Clinically significant renal or hepatic disease or any other medical disease that, in
             the opinion of the investigator, might compromise the study, including seizure

          -  Alcohol or drug abuse within the last year

          -  A recent history of myocardial infarction or unstable heart disease (within 6 months
             of baseline)

          -  Bipolar disorder

          -  For female, known or suspected pregnancy or breast feeding

          -  Use of a monoamine oxidase inhibitor (MAOI) within 14 days of baseline; use of any
             investigational drug within 30 days of baseline.

          -  Patients have prior use of venlafaxine or use of venlafaxine for the current episode.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110168</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200124</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201900</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300350</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <zip>313000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <state>Zhejiang</state>
        <zip>215008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>April 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2010</results_first_posted>
  <last_update_submitted>March 2, 2012</last_update_submitted>
  <last_update_submitted_qc>March 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in China from March 2007 to January 2008.</recruitment_details>
      <pre_assignment_details>There was no screening period for this study. Screening was done by the investigator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Venlafaxine XR</title>
          <description>75-225 mg per day</description>
        </group>
        <group group_id="P2">
          <title>SSRI or Conventional Antidepressant Group</title>
          <description>Selective serotonin reuptake inhibitor (SSRI) or Conventional Antidepressants, dependent upon the selected antidepressant, dosages ranging from 20 mg to 250 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="791"/>
                <participants group_id="P2" count="367"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="734"/>
                <participants group_id="P2" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suicide ideation/behavior</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of compliance</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Venlafaxine XR</title>
          <description>75-225 mg per day</description>
        </group>
        <group group_id="B2">
          <title>SSRI or Conventional Antidepressant Group</title>
          <description>Selective serotonin reuptake inhibitor (SSRI) or Conventional Antidepressants, dependent upon the selected antidepressant, dosages ranging from 20 mg to 250 mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="787"/>
            <count group_id="B2" value="364"/>
            <count group_id="B3" value="1151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.97" spread="12.84"/>
                    <measurement group_id="B2" value="40.49" spread="13.08"/>
                    <measurement group_id="B3" value="40.13" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="460"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="685.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="466.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving Remission</title>
        <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population is the per protocol population, consisting of patients who have received at least one dose and have completed the 12 week clinical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine XR</title>
            <description>75-225 mg per day</description>
          </group>
          <group group_id="O2">
            <title>SSRI or Conventional Antidepressant Group</title>
            <description>Selective serotonin reuptake inhibitor (SSRI) or Conventional Antidepressants, dependent upon the selected antidepressant, dosages ranging from 20 mg to 250 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Remission</title>
          <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50.</description>
          <population>The analysis population is the per protocol population, consisting of patients who have received at least one dose and have completed the 12 week clinical assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status)</title>
        <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis population is the per protocol population, consisting of patients who have received at least one dose and have completed the 12 week clinical assessment. A total of 125 (VEN XR=83, SSRI=42) patients had a co-morbid anxiety disorder and 834 (VEN XR=581, SSRI=253) did not.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine XR</title>
            <description>75-225 mg per day</description>
          </group>
          <group group_id="O2">
            <title>SSRI or Conventional Antidepressant Group</title>
            <description>Selective serotonin reuptake inhibitor (SSRI) or Conventional Antidepressants, dependent upon the selected antidepressant, dosages ranging from 20 mg to 250 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status)</title>
          <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50.</description>
          <population>The analysis population is the per protocol population, consisting of patients who have received at least one dose and have completed the 12 week clinical assessment. A total of 125 (VEN XR=83, SSRI=42) patients had a co-morbid anxiety disorder and 834 (VEN XR=581, SSRI=253) did not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Co-morbid anxiety disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No anxiety disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Venlafaxine XR</title>
          <description>75-225 mg per day</description>
        </group>
        <group group_id="E2">
          <title>SSRI or Conventional Antidepressant Group</title>
          <description>Selective serotonin reuptake inhibitor (SSRI) or Conventional Antidepressants, dependent upon the selected antidepressant, dosages ranging from 20 mg to 250 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attempted suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="418"/>
                <counts group_id="E2" subjects_affected="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Unstable blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Bitter taste</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>No appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Stomach disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Gastrointestinal reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Stomach ache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Feeble</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Abdominal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Muscular soreness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>General malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Head malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Waist disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Weight decrease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Muscel spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Waist pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anesthesia local</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Sweating increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sluggish</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dreaminess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Fidget</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Insomina</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Sexual hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Manic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Switching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dreaming abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition frequency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Oligiomenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>365 participants were assessed for safety. Certain demographic data (gender and age) is missing for one participant. Thereby resulting in the participant flow reflecting 364 participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

